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Abstract 
 
Nasopharyngeal Carcinoma (NPC) is closely associated with Epstein-Barr virus (EBV) 
infection. The EBV-encoded latent membrane protein 1 (LMP1), which is commonly 
expressed in NPC, engages multiple signaling pathways that promote cell growth, 
transformation and metabolic reprogramming. Here, we report a novel function of LMP1 in 
promoting de novo lipogenesis. LMP1 increases the expression, maturation and activation of 
sterol regulatory element-binding protein 1 (SREBP1), a master regulator of lipogenesis, and 
its downstream target: fatty acid synthase (FASN). LMP1 also induces de novo lipid 
synthesis and lipid droplet formation. In contrast, siRNA knockdown of LMP1 in EBV-
infected epithelial cells diminished SREBP1 activation and lipid biosynthesis. Furthermore, 
inhibition of the mTOR pathway, either through the use of mTOR inhibitors or siRNAs 
significantly reduced LMP1-mediated SREBP1 activity and lipogenesis, indicating that 
LMP1 activation of the mTOR pathway is required for SREBP1-mediated lipogenesis. In 
primary NPC tumors, FASN overexpression is common, with high levels correlating 
significantly with LMP1 expression. Moreover, elevated FASN was associated with 
aggressive disease and poor survival in NPC patients. Luteolin and fatostatin, two inhibitors 
of lipogenesis, suppressed lipogenesis and proliferation of nasopharyngeal epithelial cells; 
effects which were more profound in cells expressing LMP1. Luteolin and fatostatin also 
dramatically inhibited NPC tumor growth in vitro and in vivo. Our findings demonstrate that 
LMP1 activation of SREBP1-mediated lipogenesis promotes tumor cell growth and is 
involved in EBV-driven NPC pathogenesis. Our results also reveal the therapeutic potential 
of utilizing lipogenesis inhibitors in the treatment of locally advanced or metastatic NPC. 
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Introduction 
 
Non-keratinizing undifferentiated nasopharyngeal carcinoma (NPC) is a distinct type of cancer 
prevalent in southeast Asia and southern China. The unique feature of NPC is its strong 
association with Epstein-Barr virus (EBV) infection [1,2]. Among the EBV-encoded gene 
products expressed in NPC, latent membrane protein 1 (LMP1) is of particular interest as it 
displays oncogenic properties in vitro and in vivo. LMP1 is an integral membrane protein 
containing two signaling domains: CTAR1 and CTAR2. Through these two domains, LMP1 
engages multiple signaling cascades that include the Ras-ERK-MAPK, PI3K-AKT, NF-κB, 
and p38-MAPK pathways, which modulate the expression of a variety of cellular targets that 
contribute to the transforming activities of LMP1 [1-3]. Previous studies have established a 
role for LMP1 in promoting cell proliferation, transformation, cell invasion and migration, 
aerobic glycolysis and metabolic reprogramming in nasopharyngeal epithelial cells [3-5]. 
These observations imply an essential role for LMP1 in the pathogenesis of NPC.  
 
Deregulated lipid metabolism is an established hallmark of cancer. Cells obtain fatty acids 
either from the diet or through de novo lipid synthesis (lipogenesis). Normal cells rely 
primarily on dietary fatty acid for the synthesis of new structural lipids and lipogenesis is not 
universal. However, cancer cells extensively engage de novo lipogenesis to produce long-
chain fatty acids that are essential for the synthesis of glycerophospholipid membrane and 
membrane signal molecules during rapid cell proliferation (supplementary material, Figure 
S5) Fatty acids are also necessary for energy storage as lipid droplets [6-8]. Lipogenesis is 
tightly regulated by sterol regulatory element-binding protein 1 (SREBP1), a transcription 
factor that regulates transcription of most genes involved in lipogenesis [9-11]. There are two 
SREBP1 isoforms (SREBP1a and SREBP1c) encoded from SREBF1. SREBF1a and 
SREBF1c are produced from different promoters, differing only in the length of their N-
terminal transactivation domains. SREBPs are synthesized as precursor proteins bound to the 
ER membrane. After stimulation, the SREBP precursor undergoes proteolytic cleavage in the 
Golgi to release the transcriptionally active-N-terminal domain. Once mature, active SREBP1 
translocates to the nucleus, where it binds to sterol regulatory element (SRE) within its 
promoter and those of its target genes [9-11]. mTOR complex 1 (mTORC1) and 2 
(mTORC2) have been shown to regulate SREBP1 activity and lipogenesis. Activation of 
mTOR signaling by the Ras-ERK, and PI3K-AKT pathways increases expression of SREBPs 
and SREBP-mediated lipogenesis [12-14]. Numerous lipogenic genes, including fatty acid 
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synthase (FASN), are upregulated in a variety of cancers [7;8;10]. In this study, we 
demonstrate that FASN expression is common in primary NPC tumors, with higher levels 
correlating with LMP1 expression. Furthermore, LMP1 activates de novo lipogenesis and 
LMP1 activation of SREBP1-mediated lipogenesis contributes to cancer cell growth and 
tumor progression. These implicate the involvement of LMP1-mediated lipogenesis in the 
pathogenesis of EBV-infected NPC. 
 
Materials and Methods 
Cell lines, Chemicals, and Pharmacological inhibitors  
C666-1 and HK-1 NPC cell lines were maintained in RPMI 1640 supplemented with 10% 
FBS. The SV40 large T-immortalized nasopharyngeal epithelial cell line NP69 was 
maintained in keratinocyte serum-free medium (Thermo Fisher Scientific, Waltham, MA 
USA). Torin 1, Torin 2, luteolin and fatostatin were obtained from Abcam, Cambridge, UK. 
Further details are presented in supplementary material, Supplementary materials and 
methods. 
 
DNA Constructs and siRNA 
Scrambled shRNA and LMP1 shRNA vectors were generated by inserting a fragment of 
synthesized oligo with a scrambled sequence or a sequence to LMP1 into pSUPER.retro.puro 
vector (Oligoengine). The pGL2-3xSRE luciferase vector was obtained from ATCC 
(Manassas, VA, USA). pGL3-FASN was kindly provided by Dr. Qiang Liu, University of 
Saskatchewan, Canada [15]. All siRNAs were purchased from Dharmacon Inc., Lafayette, 
CO, USA. Transient transfection of siRNA or DNA was performed using Lipofectamine 
2000 (Thermo Fisher Scientific) or Fugene HD (Promega, Madison, WI, USA) respectively. 
See supplementary material, Supplementary materials and methods for addition detail. 
 
Western blotting analysis 
Total cell lysates (5–50 μg of protein) were separated by 10% or 4–12% SDS-PAGE and 
transferred to PVDF membranes prior to immunoblotting. Antibodies to LMP1 were 
purchased from Dako and α-tubulin from Santa Cruz. The anti-SREBP1 [2A4] was 
purchased from Abcam and Santa Cruz. All other antibodies were purchased from Cell 
Signaling Technology (Beverley, MA, USA). Additional details are provided in 
supplementary material, Supplementary materials and methods. 
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RT-qPCR 
All RT-qPCR products were amplified using the Power SYBR green PCR Master Mix Kit 
(Thermo Fisher Scientific). Details including primer sequences are provided in 
supplementary material, Supplementary materials and methods.  
 
Luciferase Reporter Assay 
Ten thousand HeLa or 293 cells grown in 96-well plate were co-transfected with 20 ng of the 
luciferase reporter construct together with increasing amounts of an LMP1 expression vector 
(pCDNA3-LMP1) as indicated in the Figure. Renilla pRL-SV40 vector was transfected as an 
internal control to correct for transfection efficiency. Two days post-transfection, cells were 
lysed in reporter lysis buffer and then assayed for luciferase and Renilla activities with the 
Dual-Luciferase Reporter Assay System (Promega). 
 
Immunofluorescence Staining 
Immunofluorescence staining was performed as previously described [16] and as further 
outlined in in supplementary material, Supplementary materials and methods. 
 
Lipid Droplet Fluorescence Staining  
Nile Red fluorescence staining was assessed using the Lipid Droplets Fluorescence Assay Kit 
according to the manufacturer’s protocol (Cayman Chemical, Ann Arbor, MI, USA). Details 
are provided in supplementary material, Supplementary materials and methods. 
 
Immunohistochemical Staining 
Immunohistochemical staining was performed as described previously [17]. Information 
regarding normal and tumor specimens, staining and intensity score methods are outlined in 
supplementary material, Supplementary materials and methods. 
 
Cell Proliferation Assay 
Cell proliferation assays were performed with cell proliferation reagent CCK-8 (Dojindo 
Molecular Technologies, Rockville, MD, USA and as described in supplementary material, 
Supplementary materials and methods. 
 
De Novo Lipogenesis Assay 
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For the lipogenesis assay, cells were incubated in serum-free medium containing 2.5 μCi/ml 
[1-14C] acetate for 8–12 h. After washing with PBS, cells were lysed in 0.5% Triton X-
100/PBS. Lipids were extracted by successive addition of methanol and chloroform, 
following by centrifugation. The organic phase was air-dried and re-suspended in chloroform 
for scintillation counting. Results were normalized to total protein content. Details are 
provided in supplementary material, Supplementary materials and methods. 
 
In Vivo Tumorigenicity Experiments 
The University Animal Experimentation Ethics Committee, CUHK approved the study 
protocol.  In brief, C666-1 cells (1×107) were inoculated subcutaneously into BALB/c nude 
mice. When the size of tumors reached about 50 mm3, animals were injected intravenously 
with PBS (vehicle), luteolin, or fatostatin every 2–3 d for 3 wk. At the end point, animals 
were killed and tumors were harvested. For further detail see supplementary material, 
Supplementary materials and methods.. 
 
Statistical analysis 
Statistical analyses were performed using GraphPad Prism 5.0 GraphPad Software Inc, La 
Jolla, CA, USA). P-value was calculated using either Fisher’s exact test or unpaired two-
tailed Student’s t-test. The IC50 values of inhibitors were calculated by applying the four-
parameter logistic equation to generate the Sigmoidal dose-response (variable slope) curves. 
Survival curves were analyzed using the Kaplan-Meier method, and were compared with a 
log-rank test. P-value <0.05 was considered to be statistically significant. 
 
Results 
LMP1 increases SREBP1 expression and activity 
To examine the impact of LMP1 on SREBP1-mediated lipogenesis, increasing amounts of an 
LMP1 expression vector was transfected into the nasopharyngeal epithelial cell line, NP69. 
Under serum-deprived conditions, a dose-dependent induction of SREBF1a and SREBF1c 
mRNA was observed (Figure 1A). Similarly, LMP1 increased the levels of both precursor 
and mature forms of SREBP1 protein (Figure 1C). SREBP1 transactivates target genes by 
binding to SRE elements within the promoter region. Using a pGL2-3xSRE reporter 
construct containing 3 tandem copies of an SRE/SP1 element [18], we found that LMP1 
increased SREBP1 transcriptional activity (Figure 1B). FASN is a transcriptional target of 
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SREBP1. FASN promoter activity was also strongly enhanced in response to LMP1 
expression (Figure 1B). The expression of FASN mRNA and protein were also induced by 
LMP1 (Figure 1A & 1C). These findings suggest that FASN induction by LMP1 is mediated 
primarily through modulation of the expression and activity of SREBP1. Both the mTORC1 
and mTORC2 pathways are involved in regulating SREBP1 activity [12-14]. LMP1 has been 
reported to activate the mTOR signaling pathway [18-20]. Here, we further confirmed that 
LMP1 induced phosphorylation of 4E-BP1 and p70S6K, two established downstream targets 
of mTOR signaling (Figure 1C). 
 
In nasopharyngeal epithelial cells stably expressing LMP1 we also observed increased 
activities of the SREBP1 and mTOR pathways (Figure 1D). Immunofluorescence staining 
revealed overexpression of FASN in LMP1-expressing nasopharyngeal epithelial cells 
(Figure 1E). To determine whether LMP1 promotes de novo lipogenesis, LMP1-expressing 
cells were labelled with 14C-acetate for 8–12 h under serum-deprived conditions. The 14C 
labelled lipid fraction was then extracted for quantification. As shown in Figure 1F, LMP1-
expressing cells produced more newly synthesized lipid than control cells. Furthermore, Nile 
Red staining revealed more intracellular lipid droplets in LMP1-expressing cells (Figure 1G, 
H). Overall, these data indicate a role for LMP1 in promoting lipid biosynthesis.  
 
LMP1 Promotes SREBP1-Mediated Lipogenesis In EBV-Infected NPC Cells 
In NPC xenografts (C17, X2117, and C15), western blotting analysis revealed higher levels 
of the precursor and mature forms of SREBP1 and FASN in LMP1-positive X2117 and C15 
compared to the LMP1 negative C17 xenograft and EBV negative non-malignant NP69 
nasopharyngeal epithelial cell line (Figure 2A). In NPC cell lines, the levels of mature 
SREBP1 and FASN proteins were higher in EBV-infected HK1-EBV and C666-1 cells 
compared to HK-1 cells (Figure 2B). Similarly, levels of the phosphorylated forms of 4E-
BP1 and p70S6K were elevated in HK1-EBV and C666-1 cells (Figure 2B). A role for LMP1 
in these effects was established, as siRNA silencing of LMP1 in EBV-infected cells resulted 
in reducing the expression of mature SREBP1 and FASN as well as the signaling activity of 
mTOR (Figure 2C). Furthermore, LMP1 silencing in C666-1 cells resulted in a decrease in 
FASN promoter activity (supplementary material, Figure S1) as well as lipogenesis, 
particularly under serum-deprived condition (Figure 2D). These data suggest that SREPB1-
mediated lipogenesis in EBV-infected cells is induced by LMP1 through the mTOR signaling 
pathway.  
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LMP1 induces SREBP1-mediated lipogenesis through the mTOR signaling pathway 
To investigate whether LMP1-induced lipogenesis was dependent on mTOR signaling, 
NP69-pLNSX and NP69-LMP1 cells were treated with the mTOR inhibitors, Torin 1 and 
Torin 2. Torin 1 is documented to inhibit both mTORC1 and mTORC2 complexes, while 
Torin 2 inhibits the mTORC1 complex [21,22]. 14C-acetate incorporation assays revealed that 
these two mTOR inhibitors could suppress lipogenesis in both cell lines, although the effects 
were more profound in LMP1-expressing cells. As shown in Figure 3A, NP69-LMP1 cells 
exhibited 53-72% reduction in lipogenesis, while only a 15-39% reduction was observed in 
NP69-pLNSX cells. To further determine whether LMP1 induction of mTOR signaling 
promoted SREBP1-mediated lipogenesis, NP69 cells were transiently transfected with an 
LMP1 expression vector together with siRNAs targeting Raptor to inhibit mTORC1 
signaling, Rictor to inhibit mTORC2 signaling, or mTOR to inhibit both mTORC1 and 
mTORC2 signaling pathways. As shown in Figure 3B, inhibition of either mTORC1, 
mTORC2 or both, reduced LMP1-induced FASN expression and SREBP1 maturation. Also, 
NP69-LMP1 cells exhibited 20-35% reduction in lipogenesis, while a 14–27% reduction was 
observed in control NP69-pLNSX cells (Figure 3C). These finding indicated that mTOR 
signaling contributes to LMP1-induced lipogenesis.  
 
Expression of FASN correlates with LMP1 expression in NPCs and poor prognosis in NPC 
patients 
To examine the expression of FASN in NPC, we performed immunohistochemical staining 
for FASN and LMP1 in 38 NPC primary tumors. The intensity of FASN staining was scored, 
and a graph of the statistical dot-plot of FASN staining intensity against LMP1 expression 
was generated (Figure 4B). Immunohistochemical staining revealed a negative or low 
expression of FASN (immunoreactivity score <3) in normal nasopharyngeal epithelium 
(Figure 4A, N1) and 16 of 38 (42%) NPC tumors in which LMP1 expression was barely 
detected (Figure 4A, representative NPC: T4). In contrast, moderate or high levels of FASN 
(immunoreactivity score ≥3) were observed in 22 of 38 NPC tumors (58%) (Figure 5A, 
representative NPC: T13, T22 & T34). In particular, LMP1-positive tumors displayed 
significantly higher levels of FASN (p=0.0003) (Figure 4B). In analysis of FASN expression 
with clinicopathological variables including gender, age, tumor size, lymph node and cancer 
stage, in NPC patients, we found that higher levels of FASN expression (score ≥3) 
significantly correlated to advanced primary tumor T3-T4 (p=0.012) and distant lymph node 
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metastasis N1-N3 (p=0.005) of NPC (supplementary material, Table S1). Also, Kaplan-Meier 
survival analysis revealed that elevated FASN expression significantly correlated to poor 
survival (p = 0.02) (Figure 4C). Overall, these findings indicate that FASN overexpression is 
common in NPC and correlated with LMP1 expression. Moreover, the elevated FASN is 
associated with aggressive disease and poor prognosis in NPC patients. These also imply a 
role of LMP1 in up-regulating FASN for NPC progression.  
 
LMP1 induction of lipid synthesis contributes to cell growth 
Next, we examine whether LMP1 induction of lipogenesis contributed to cell growth. NP69 
and HK1 cells expressing pLNSX control or LMP1 were treated with luteolin, or fatostatin. 
Luteolin is an inhibitor which suppresses SREBP-mediated lipogenesis. Fatostatin is an 
SREBP specific inhibitor [23-25]. 14C-acetate incorporation assays revealed that these 
inhibitors could dampen lipogenesis in all cell lines; however, the repression was more 
evident in LMP1 expressing cells (Figures 5A,B). Fatostatin and luteolin treatment reduced 
lipogenesis of NP69-pLNSX cells by 35-70%, while, a 54-87% reduction was observed in 
NP69-LMP1 cells (Figure 5A). Similarly, fatostatin and luteolin reduced lipogenesis in HK1-
pLNSX cells by 28-46% and in HK1-LMP1 cells by 50-69% (Figure 5B). Western blot 
analysis confirmed that both luteolin and fatostatin effectively inhibited SREBP1 maturation 
and FASN expression in NP69-LMP1 and HK1-LMP1 cells (supplementary material, Figure 
S2).  
 
To determine whether lipogenesis conferred a growth advantage to LMP1-expressing cells, 
pLNSX control and LMP1 expressing NP69 and HK-1 cells were grown in culture medium 
supplemented with 1% serum together with increasing doses of luteolin or fatostatin for 1–4 
days, and the effects on cell growth examined. As shown in Figures 5D-5G, inhibition of 
fatty acid synthesis by luteolin or fatostatin reduced the proliferation of both control and 
LMP1 expressing cells, although NP69-LMP1 and HK1-LMP1 cells appeared more 
susceptible to the actions of both drugs. The IC50 values of luteolin at day 3 in NP69-pLNSX, 
NP69-LMP1, HK1-pLNSX and HK1-LMP1 cells were 2.6 μM, 1.14 μM, 12.4 μM and 
5.6 μM, respectively. Similarly, the IC50 values of fatostatin at day 3 in NP69-pLNSX, NP69-
LMP1, HK1-pLNSX and HK1-LMP1 cells were 6.5 μM, 2.9 μM, 5.6 μM and 3.3 μM, 
respectively. Also, these two inhibitors suppressed lipogenesis in C666-1 NPC cells by 50% 
(Figure 5C) and inhibited their proliferation; the IC50 value of luteolin and fatostatin at day 4 
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were 9.6 μM and 25.5 μM respectively (Figures 5H,I). These findings indicate that 
suppression of lipogenesis inhibits LMP1-induced proliferation in both malignant and non-
malignant nasopharyngeal epithelial cells, implicating the induction of lipogenesis by LMP1 
as an essential mechanism in facilitating cell proliferation. 
 
Inhibitors of lipogenesis suppress NPC growth and induce apoptosis in vivo 
Next, we examined whether blocking lipogenesis inhibited the growth of NPC tumor in vivo. 
C666-1 cells were subcutaneously injected into the flanks of nude mice. Once tumors reached 
50mm3 in size, the mice were injected intraperitoneally with PBS, luteolin (20mg/kg), or 
fatostatin (15mg/kg) every 2-3 days for 19 days. Body weight and tumor size were measured 
every several days. At the endpoint, animals were killed and tumors were harvested. Both 
luteolin and fatostatin significantly inhibited tumor growth in mice (p<0.0001) (Figure 6A). 
In animals treated with luteolin or fatostatin, substantially lower tumor weights and smaller 
tumor size were observed (p<0.0001) (Figure 6B,C). Surprisingly, no noticeable weight loss 
was observed in treated animals with either drug (supplementary material, Figure S3). 
Immunohistochemical staining analysis of NPC tumors from these two groups of mice 
indicated that both luteolin and fatostatin effectively inhibit FASN expression (Figure 6D & 
supplementary material, Figure S4). In addition, histological investigations of tumor tissues 
revealed more pronounced necrosis in both luteolin (35%) and fatostatin (43%) treated 
groups compared to the control (5%) group (Figure 6D). An examination of cell proliferation 
by IHC staining for Ki67; and apoptosis by staining for cleaved capase-3 (CC3), revealed that 
both drugs significantly inhibited cell proliferation and increased apoptosis. As shown in 
Figure 6D, the amount of Ki67 positive cells was markedly lower in the tumor tissues of 
luteolin (56%) and fatostatin (45%) treated groups compared to the control group (70%). 
Also, the percentage of cleaved Caspase-3 (CC3) positive cells were significantly high in 
luteolin (36%) and fatostatin (31%) treated groups when compared to (12%) control group. 
Western blotting analysis further confirmed induction of CC3 and cleaved PARP in luteolin 
and fatostatin treated tumors (supplementary material, Figure S4). These findings indicate 
that inhibition of lipogenesis by luteolin and fatostatin causes cell apoptosis and necrosis, 
leading to tumor growth suppression.  
 
Discussion 
The oncogenic LMP1 protein is frequently found to be expressed in NPC tumors. While, 
LMP1 promotes cell growth, transformation, invasion and migration, it also plays a role in 
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modulating host cell metabolic pathways [1,3,26]. In previous studies, we have demonstrated 
an ability of LMP1 to promote aerobic glycolysis through constitutive activation of 
FGF2/FGFR1 signaling pathway and upregulation of c-Myc and HIF-1α, two primary 
regulators of aerobic glycolysis [5]. LMP1 also inactivates LKB1-AMPK to promote 
proliferation and anchorage-independent growth [4]. Here, we report a novel function of 
LMP1 in promoting SREBP1-mediated de novo lipogenesis, an effect that facilitates cell 
growth and tumor development (supplementary material, Figure S5).  
 
In this study, we show that LMP1 increases SREBP1 expression and activity in 
nasopharyngeal epithelial cells. Luciferase promoter reporter assays and RT-qPCR analysis 
demonstrate that LMP1 upregulates SREBP1 at the transcriptional level (Figures 1A & 1B), 
while western blotting analysis revealed that LMP1 promotes SREBP1 maturation and the 
expression of its downstream target, FASN (Figures 1C,D). Using 14C-acetate incorporation 
assay, we demonstrate an ability of LMP1 to promote lipogenesis (Figure 1F). Interestingly, 
silencing LMP1 in EBV-infected NPC cells resulted in a reduction in FASN expression and 
lipogenesis (Figures 2C,D). Furthermore, suppressing lipogenesis by inhibitors significantly 
reduced LMP1-induced proliferation (Figure 5). Collectively, these findings demonstrate that 
LMP1 induction of lipogenesis in NPC contributes to cell proliferation.  
 
SREBPs tightly regulate lipogenesis. However, the mechanism underlying the expression and 
activity of SREBPs is still unclear. Hypoxia, glucose and insulin have been found to increase 
the expression of SREBPs [10]. Interestingly, we and others have reported a function of 
LMP1 in promoting HIF-1 expression and glucose uptake [5;26]. mTORC1 and mTORC2 
have been shown to regulate SREBP activity and lipogenesis through multiple inputs [27-
30]. Here, in line with other studies [18-20], we demonstrate that LMP1 increases the 
phosphorylation of 4E-BP1 and p70S6K, two established targets of mTOR, in 
nasopharyngeal epithelial cells (Figures 1-3). Using siRNAs targeting Raptor or Rictor, we 
show that both mTORC1 and mTORC2 signaling pathways are involved in LMP1-mediated 
lipogenesis (Figure 3). The mTOR signaling pathway is complicated as it contains both 
positive and negative feedback loops, and its downstream signaling interconnects with other 
cell growth and survival pathways [28-31]. mTORC2 is activated by ribosomes and PI3K 
signaling and is negatively regulated by a mTORC1-induced p70S6 kinase, which dampens 
PI3K signaling by inhibiting IRS-1 [28-31]. mTORC1 activity is induced by PI3K-AKT, 
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Ras-ERK-MAPK, IKKα-NFαB and IKKβ-NFαB pathways, all of which inhibit Tuberous 
Sclerosis Complex (TSC), a critical negative regulator of mTORC1. mTORC2-induced AKT 
signaling also activates mTORC1. In contrast, LKB1-AMPK inhibits mTORC1 through 
activating TSC2 and inactivating Raptor [28-31]. Interestingly, AMPK is an inhibitory target 
of LMP1 [4]. PI3K-AKT, Ras-ERK-MAPK, and NFκB are three major pathways engaged by 
LMP1 [2;3]. As such, LMP1 induction of mTOR-SREBP-induced lipogenesis appears to be 
mediated through multiple downstream targets and/or signaling pathways.  
 
Overexpression of FASN has been documented in oral hairy leukoplakia (OHL), an EBV-
associated benign lesion associated with robust EBV lytic replication [32]. FASN is induced 
by the EBV-encoded lytic protein, BRLF-1 through the p38-MAPK pathway and required for 
lytic viral gene expression [32]. In a similar vein, HBV and HCV lytic infection in liver 
cancer cells is associated with the induction of fatty acid synthesis for the formation of viral 
envelopes [33-35]. Another γ-herpesvirus, KSHV, has been shown to induce FASN 
expression and fatty acid synthesis for the survival of latently infected PEL cells [36]. Here, 
we found higher levels of SREBP1 activation and FASN expression in EBV latently infected 
NPC cells and xenografts, where LMP1 was expressed (Figure 2). While normal 
nasopharyngeal epithelium showed negative expression of FASN and LMP1 (Figure 4A), 
high level of FASN expression in NPC primary tumors was common and correlated 
significantly with LMP1 expression (Figure 4A,B). In line with previous studies, elevated 
FASN expression was significantly associated with T3-T4 staged primary tumors, N1-N3 
lymph node metastasis and poor overall survival of NPC patients  (Figure 4C & 
supplementary material, Table S1) [37]. These findings suggest that LMP1 induction of 
FASN and lipogenesis is involved in NPC progression. Of the LMP1-negative NPC tumors 
examined, 9/25 (36%) displayed a moderate or high level of FASN (Figure 4B). Our 
previous genetic analyses indicated that somatic mutations and/or aberrant expression of 
signaling proteins (LTBR, PIK3CA, p50, RelB, Bcl3, EGFR and RAS), or signaling 
regulators (INPP4B, TRAF3, TRAF2, A20, NFKBIA, TNFAIP3, and CYLD) are common in 
NPC, resulting in constitutive activation of the ERK1/2, NFκB and PI3K/AKT pathways [38-
40]. Therefore, the genetic background of NPC tumors, in addition to LMP1 expression, is 
likely to contribute to FASN upregulation. 
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Given that FASN is commonly increased in virus-associated cancers, lipogenesis appears to 
be essential for viral infection and cancer progression [35]. As lipogenesis is not common in 
normal cells, targeting lipogenesis (or lipogenic pathways) might selectively inhibit the 
growth of virus-infected cells as well as highly proliferative cancer cells in the early stage of 
cancer development. In this study, we examined the effects of fatostatin and luteolin on cell 
growth and tumor development in relation to NPC. Fatostatin is a small molecule, which 
specifically blocks proteolytic activation of SREBPs [24]. Luteolin is a plant flavonoid, 
which possesses inhibitory effects on lipogenesis [23]. Both fatostatin and luteolin 
significantly inhibit SREBP1 activity, lipid synthesis and cell proliferation induced by LMP1 
(Figure 5 & Supplementary Figure S2). Interestingly, luteolin has been reported to inhibit 
PI3K-AKT, MAPK-ERK and mTOR signaling activities [41], the major pathways required 
for SREBP-mediated lipogenesis by LMP1. Moreover, fatostatin and luteolin significantly 
inhibit the proliferation and tumorigenic growth of C666-1 cells. In nude mice, fatostatin and 
luteolin at a doses which effectively downregulates FASN expression, brought about a 
marked reduction in tumor growth (Figures 6 & supplementary material, Figure S4). 
Surprisingly, no significant weight loss was observed in animals treated with luteolin or 
fatostatin (supplementary material, Figure S3). The promising effects of these inhibitors in 
suppressing NPC tumor growth with low-level toxicity suggest a possible clinical utility in 
the treatment of NPC. Luteolin is a dietary flavonoid found in vegetables, fruits and herbs. In 
addition to its inhibitory effect on lipogenesis, luteolin also suppresses inflammation, 
angiogenesis, cell proliferation, and metastasis, all of which associated with cancer 
development [41]. Interestingly, luteolin has been shown to induce G1 arrest and inhibit EBV 
reactivation in NPC cells [42,43]. Given that luteolin is a natural polyphenolic compound and 
its toxicity is barely highlighted, it may prove to be a promising compound for the inhibition 
of EBV infection and the treatment of EBV-associated cancers. The potential of luteolin for 
the treatment of EBV-associated malignancies is worth to be further evaluated, particularly in 
clinical trials.  
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Figure Legends 
Figure 1. Induction of SREBP1 expression and activity by LMP1. (A) NP69 cells 
transfected with increasing amounts of an LMP1 expression vector as indicated were 
subjected to RT-qPCR analysis for SREBF1a, SREBF1c, LMP1 and FASN. The mRNA 
expression of the target gene of interest was normalized to expression of the TBP gene. 
Relative mRNA levels were calculated using the sample without the LMP1 expression vector 
(set at 1). (B) HEK-293 cells were transfected with various amounts of an LMP1 expression 
vector together with luciferase promoter vector: pGL2-3xSRE or pGL3-FASN. After serum-
deprivation for 12 h, cells were harvested for reporter activity analysis. The firefly luciferase 
activity was normalized to Renilla luciferase activity and plotted relative to the sample 
without the LMP1 expression vector (set at 1). (C) NP69 cells transfected with increasing 
amounts of an LMP1 expression vector as indicated or (D) NP69 and HK1 cells stably 
expressing LMP1 were incubated in serum-free medium for 12 h, prior to immunoblotting 
analysis; (E) immunofluorescence staining of FASN; (F) 14C-acetate incorporation assay for 
measurement of de novo lipid synthesis; and (G) Nile Red fluorescence staining for lipid 
droplets and counterstained with Hoechst 33342 to stain cell nuclei. As a positive control for 
lipid droplet staining (Right panel), pLNSX control cells were incubated in medium 
supplemented with oleic acid for 12 h prior to staining. Nile Red fluorescence (ex/em 
385/535 nm) and Hoechst 33342 fluorescence (ex/em 355/460 nm). (H) The relative amount 
of lipid droplet formation was calculated by normalising the Hoechst 33342 fluorescence to 
the Nile Red signal in each well and compared to pLNSX vector control sample (set at 1). 
Data represent the means of 8 determinations. Mean and SD. ***, p <0.001.  
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SUPPLEMENTARY MATERIAL ONLINE 
 
Supplementary materials and methods  YES 
 
Supplementary figure legends  No because legends are embedded in the Suppl Figures PDF 
 
Figure S1. Silencing of LMP1 leads to a reduction of FASN promoter activity 
 
Figure S2. The inhibitory effects of luteolin and fatostatin on SREBP1 maturation and FASN 
expression 
 
Figure S3. Body weight of mice bearing C666-1 NPC xenografts during the course of 
treatment with either PBS (control), luteolin, or fatostatin 
 
Figure S4. The inhibitory effects of Luteolin and Fatostatin on FASN expression, cell 
proliferation and apoptosis in NPC xenografts 
 
Figure S5. The mechanism of LMP1 in upregulation of lipogenesis 
 
Table S1. Clinicopathologic characteristics of patients with NPC 
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